Is Kiniksa Pharmaceuticals Stock a Good Investment?
Kiniksa Pharmaceuticals Investment Advice | KNSA |
- Examine Kiniksa Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Kiniksa Pharmaceuticals' leadership team and their track record. Good management can help Kiniksa Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Kiniksa Pharmaceuticals' business and its evolving consumer preferences.
- Compare Kiniksa Pharmaceuticals' performance and market position to its competitors. Analyze how Kiniksa Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Kiniksa Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Kiniksa Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Kiniksa Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Kiniksa Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Kiniksa Pharmaceuticals Stock
Researching Kiniksa Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The book value of Kiniksa Pharmaceuticals was now reported as 6.06. The company has Price/Earnings To Growth (PEG) ratio of 0.25. Kiniksa Pharmaceuticals recorded a loss per share of 0.12. The entity had not issued any dividends in recent years. The firm had 1:1 split on the 28th of June 2024.
To determine if Kiniksa Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Kiniksa Pharmaceuticals' research are outlined below:
| Kiniksa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Kiniksa Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Baker Bros. Advisors Lp of 4730 shares of Kiniksa Pharmaceuticals subject to Rule 16b-3 |
Kiniksa Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Kiniksa Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kiniksa Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Kiniksa Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Kiniksa Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-07-23 | 2024-06-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2023-10-31 | 2023-09-30 | -0.17 | -0.2 | -0.03 | 17 | ||
2023-05-02 | 2023-03-31 | -0.21 | -0.18 | 0.03 | 14 | ||
2022-05-03 | 2022-03-31 | -0.41 | -0.36 | 0.05 | 12 | ||
2020-11-05 | 2020-09-30 | -0.6 | -0.66 | -0.06 | 10 | ||
2024-04-23 | 2024-03-31 | -0.16 | -0.25 | -0.09 | 56 | ||
2022-02-22 | 2021-12-31 | -0.42 | -0.53 | -0.11 | 26 | ||
2019-03-07 | 2018-12-31 | -0.75 | -0.88 | -0.13 | 17 |
Kiniksa Pharmaceuticals Target Price Consensus
Kiniksa target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Kiniksa Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Kiniksa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Kiniksa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Kiniksa Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationKiniksa Pharmaceuticals Target Price Projection
Kiniksa Pharmaceuticals' current and average target prices are 19.66 and 36.00, respectively. The current price of Kiniksa Pharmaceuticals is the price at which Kiniksa Pharmaceuticals is currently trading. On the other hand, Kiniksa Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Kiniksa Pharmaceuticals Market Quote on 1st of February 2025
Target Price
Analyst Consensus On Kiniksa Pharmaceuticals Target Price
Kiniksa Pharmaceuticals Analyst Ratings
Kiniksa Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Kiniksa Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Kiniksa Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Kiniksa Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Kiniksa Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kiniksa Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiniksa Pharmaceuticals backward and forwards among themselves. Kiniksa Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kiniksa Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-09-30 | 741.3 K | Driehaus Capital Management Llc | 2024-09-30 | 730.9 K | State Street Corp | 2024-09-30 | 704.7 K | Fmr Inc | 2024-09-30 | 696.8 K | Rice Hall James & Associates, Llc | 2024-09-30 | 649.6 K | Tang Capital Management Llc | 2024-09-30 | 628.6 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 531.3 K | Millennium Management Llc | 2024-09-30 | 516.5 K | Goldman Sachs Group Inc | 2024-09-30 | 508.4 K | Blackrock Inc | 2024-09-30 | 3.8 M | Vanguard Group Inc | 2024-09-30 | 3.3 M |
Kiniksa Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.44 B.Market Cap |
|
Kiniksa Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.02 | 0.03 | |
| Return On Capital Employed | (0.05) | (0.05) | |
| Return On Assets | 0.02 | 0.03 | |
| Return On Equity | 0.04 | 0.04 |
Determining Kiniksa Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Kiniksa Pharmaceuticals is a good buy. For example, gross profit margin measures Kiniksa Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Kiniksa Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Kiniksa Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kiniksa Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kiniksa Pharmaceuticals' management manipulating its earnings.
Evaluate Kiniksa Pharmaceuticals' management efficiency
Kiniksa Pharmaceuticals has return on total asset (ROA) of (0.0316) % which means that it has lost $0.0316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0215) %, meaning that it created substantial loss on money invested by shareholders. Kiniksa Pharmaceuticals' management efficiency ratios could be used to measure how well Kiniksa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Kiniksa Pharmaceuticals' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Capital Employed is forecasted to decline to (0.05). At present, Kiniksa Pharmaceuticals' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 301.9 M, whereas Total Assets are forecasted to decline to about 309.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.64 | 2.98 | |
| Tangible Book Value Per Share | 5.42 | 2.90 | |
| Enterprise Value Over EBITDA | (44.62) | (42.39) | |
| Price Book Value Ratio | 2.52 | 2.65 | |
| Enterprise Value Multiple | (44.62) | (42.39) | |
| Price Fair Value | 2.52 | 2.65 | |
| Enterprise Value | 1 B | 597.1 M |
Leadership at Kiniksa Pharmaceuticals emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 0.348 |
Basic technical analysis of Kiniksa Stock
As of the 1st of February, Kiniksa Pharmaceuticals secures the Standard Deviation of 2.96, risk adjusted performance of (0.11), and Mean Deviation of 1.97. Kiniksa Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.Kiniksa Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kiniksa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kiniksa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kiniksa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kiniksa Pharmaceuticals' Outstanding Corporate Bonds
Kiniksa Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kiniksa Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kiniksa bonds can be classified according to their maturity, which is the date when Kiniksa Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Kiniksa Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Kiniksa Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.85) | |||
| Mean Deviation | 1.97 | |||
| Coefficient Of Variation | (716.14) | |||
| Standard Deviation | 2.96 | |||
| Variance | 8.74 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (0.74) | |||
| Treynor Ratio | (0.86) | |||
| Maximum Drawdown | 17.59 | |||
| Value At Risk | (4.45) | |||
| Potential Upside | 2.67 | |||
| Skewness | (2.46) | |||
| Kurtosis | 10.54 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.85) | |||
| Mean Deviation | 1.97 | |||
| Coefficient Of Variation | (716.14) | |||
| Standard Deviation | 2.96 | |||
| Variance | 8.74 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (0.74) | |||
| Treynor Ratio | (0.86) | |||
| Maximum Drawdown | 17.59 | |||
| Value At Risk | (4.45) | |||
| Potential Upside | 2.67 | |||
| Skewness | (2.46) | |||
| Kurtosis | 10.54 |
Consider Kiniksa Pharmaceuticals' intraday indicators
Kiniksa Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kiniksa Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Kiniksa Pharmaceuticals Corporate Filings
F4 | 15th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 21st of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Kiniksa Stock media impact
Far too much social signal, news, headlines, and media speculation about Kiniksa Pharmaceuticals that are available to investors today. That information is available publicly through Kiniksa media outlets and privately through word of mouth or via Kiniksa internal channels. However, regardless of the origin, that massive amount of Kiniksa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kiniksa Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kiniksa Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kiniksa Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kiniksa Pharmaceuticals alpha.
Kiniksa Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Kiniksa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kiniksa Pharmaceuticals Corporate Management
| Madelyn Zeylikman | General SVP | Profile | |
| Melissa Manno | Senior Officer | Profile | |
| Ross Moat | Senior Officer | Profile | |
| Rachel Frank | Senior Communications | Profile | |
| Michael CPA | Chief Finance | Profile | |
| Chad Morin | Senior Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.674 | Return On Assets |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Kiniksa Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.